Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Psychosis and schizophrenia in children and young people: recognition and management

Clinical guideline
Reference number: CG155
Published: 23 January 2013
Last updated: 26 October 2016

Register as a stakeholder

Schizophrenia up to 18 years of age: scoping workshop notes

Schizophrenia up to 18 years of age: scoping workshop notes

Schizophrenia up to 18 years of age: scoping workshop notes
20 December 2010
(88.82 Kb 25 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 17 December 2010

Surveillance review decision (PDF 291 KB)

Published:

06 May 2015
Evidence update (PDF 806 KB)

Published:

15 May 2015
Equality impact assessment form (PDF 124 KB)

Published:

23 January 2013
Final comments table (PDF 510 KB)

Published:

23 January 2013
Full guideline (PDF 3.28 MB)

Published:

09 August 2012
Appendices (PDF 4.27 MB)

Published:

09 August 2012
NICE guideline (PDF 445 KB)

Published:

09 August 2012
List of registered stakeholders (PDF 26 KB)

Published:

09 August 2012
Economic plan (PDF 12 KB)

Published:

26 June 2012
Search strategies (PDF 390 KB)

Published:

25 June 2012
Protocol (PDF 587 KB)

Published:

25 June 2012
Review questions (PDF 174 KB)

Published:

25 June 2012
Remit (PDF 10 KB)

Published:

25 March 2010
Equalities impact assessment (scoping) (PDF 53 KB)

Published:

29 June 2011
Scope consultation comments table with developer's responses (PDF 447 KB)

Published:

01 July 2011
Final scope (PDF 80 KB)

Published:

24 June 2011
Schizophrenia up to 18 years of age: draft scope (PDF 71 KB)

Published:

20 December 2010
Schizophrenia up to 18 years of age: scoping workshop notes (PDF 89 KB)

Published:

20 December 2010
List of registered stakeholders (PDF 26 KB)

Published:

09 August 2012
GDG membership list (PDF 58 KB)

Published:

10 February 2012
GDG 9 & 10 - 15-16 May 2012 (PDF 86 KB)

Published:

20 June 2012
GDG 8 - 21 March 2012 (PDF 90 KB)

Published:

28 May 2012
GDG 7 - 8 February 2012 (PDF 76 KB)

Published:

28 May 2012
GDG 6 - 16 December 2011 (PDF 31 KB)

Published:

10 February 2012
GDG 5 - 8 November 2011 (PDF 43 KB)

Published:

10 February 2012
GDG 4 - 22 July 2011 (PDF 32 KB)

Published:

10 February 2012
GDG 3 - 21 June 2011 (PDF 32 KB)

Published:

10 February 2012
GDG 2 - 4 May 2011 (PDF 40 KB)

Published:

10 February 2012
GDG 1 - 22 March 2011 (PDF 42 KB)

Published:

10 February 2012